Dr. Jason N. Rogart, MD

Dr. Rogart practices at Capital Health Medical Center - Hopewell in Pennington, New Jersey, part of Capital Health System.

Dr. Rogart's NPI, 1477648426, was assigned on October 4, 2006. Dr. Rogart graduated from Warren Alpert Medical School of Brown University in 1997. Dr. Rogart holds New Jersey license 25MA08498000.

Dr. Rogart's primary practice is Capital Health Medical Center - Hopewell, at One Capital Way, Pennington, NJ 08534 in Mercer County. The practice phone is (609) 303-4000. Dr. Rogart also practices at Capital Health Medical Center - Hopewell, 1 Capital Way, Pennington, NJ 08534.

Dr. Rogart's primary practice is Capital Health Medical Center - Hopewell in Pennington, New Jersey, part of Capital Health System. Dr. Rogart is also affiliated with Capital Health Regional Medical Center. The medical group on file is Capital Health Medical Group. Dmand AI also links Dr. Rogart to 1 more hospital and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Rogart practices, 4 sites in all. Vendor and product names are available with a free account.

Gastroenterology is Dr. Rogart's primary specialty in the NPI Registry, under taxonomy code 207RG0100X. Dmand AI has Dr. Rogart's licenses on file in 2 states: New Jersey and Connecticut.

CMS data shows 813 Medicare services from Dr. Rogart across 16 procedure codes in 2024, for 330 Medicare patients. Medicare paid $81,913 for them.

CMS counts 330 Medicare patients who saw Dr. Rogart in 2024. The largest group is 65 to 74, with 158 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 9% are also on Medicaid. Their average risk score is 1.34, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Rogart's median patient age at 70, with 54% women.

In 2024, Dr. Rogart wrote 414 Medicare Part D claims for 243 patients. 73% of them were for generic drugs. CMS names the drug for 350 of them, across 9 drugs with 11 or more claims each, at $69,600 in total drug cost. In 2023, CMS named 267 claims across 8 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 97 out of 100 for Dr. Rogart for performance year 2024, reported through an alternative payment model (APM). Dr. Rogart accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 771 procedures of upper gastrointestinal (gi) endoscopy for acid reflux by Dr. Rogart, more than 99% of the clinicians it reports for that procedure.

Dmand AI links 7 papers to Dr. Rogart, published from 2010 to 2018. The most frequent topics are Biopsy, Fine-Needle, Carcinoembryonic Antigen and Endoscopy, Gastrointestinal. Dr. Rogart has published most often in J Clin Gastroenterol. Dr. Rogart's most frequent co-authors are Tamas A. Gonda, MD, Susana Gonzalez, MD and Mouen A. Khashab, MD.

CMS Open Payments shows 171 general payments to Dr. Rogart from 14 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 59% of the total. Boston Scientific Corporation paid the most, $35,253.

Dr. Rogart graduated from Warren Alpert Medical School of Brown University in 1997.